巴瑞替尼治疗难治性肠白塞病疗效分析OA
Efficacy of baricitinib in patients with refractory intestinal Behçet's disease
目的 探讨巴瑞替尼在难治性肠白塞病患者中的疗效.方法 回顾性分析北京协和医院2020 年 10 月至2026 年3 月接受巴瑞替尼治疗的肠白塞病患者临床资料.结果 共纳入 32 例难治性肠白塞病患者,其中男性 18 例,女性 14 例,中位年龄35 岁,中位病程36 个月.19 例(59.4%)表现为多发溃疡,回肠、回盲部或结肠活动性溃疡 30 例(93.8%).其中 19 例(59.4%)使用巴瑞替尼3~4 mg/d(高剂量组),13 例使用2 mg/d(低剂量组).治疗 6 个月后,总体 DAIBD 临床缓解率46.4%,临床应答率71.4%,9/20 例(45.0%)实现内镜下黏膜完全缓解,6/20 例(30.0%)显著改善/改善;治疗后 12 个月后,9/18 例(50.0%)达到黏膜完全缓解,6/18 例(33.4%)显著改善/改善.巴瑞替尼高剂量组在炎症指标改善及 DAIBD 评分降低方面显著优于低剂量组.结论 肠白塞病治疗棘手,本研究结果提示巴瑞替尼可能对难治性肠白塞病具有一定疗效.
Objective To explore the efficacy of baricitinib in patients with refractory intestinal Behçet's disease.Methods We retrospectively reviewed the clinical data of 32 patients with refractory intesti-nal Behçet's disease who received baricitinib treatment at Peking Union Medical College Hospital from October 2020 to March 2026.The efficacy and safety of baricitinib treatment were analyzed.Results All 32 patients(including 18 males and 14 females)had a median age of 35 years and a median disease duration of 36 months.Nineteen patients(59.4%)presented with multiple intestinal ulcers,and 30 patients(93.8%)had active ulcers in the ileum,ileocecal area,or colon.Among the 32 patients,19(59.4%)received baricitinib at 3-4 mg daily,and 13 received 2 mg daily.After 6 months of treatment,the total DAIBD remission rate was 46.4%and the clinical response rate was 71.4%;complete mucosal healing was achieved in 9/20 patients(45.0%),and marked improvement/improvement was observed in 6/20 patients(30.0%).After 12 months of treatment,complete mucosal healing was achieved in 9/18 patients(50.0%),and marked improvement/improvement was found in 6/18 patients(33.4%).The high-dose baricitinib group was significantly superior to the low-dose group in improving inflammatory markers and reducing DAIBD scores.Conclusions Refractory intestinal Behçet's disease is a severe complication of Behçet's syndrome,and thus requires early identifica-tion and active intervention.The results of this study suggested that baricitinib might be effective for refractory intestinal Behçet's disease.
乔琳;王之冕;刘烨玲;敖懿源;柏小寅;杨红;赵岩;刘金晶;郑文洁
100730 北京,中国医学科学院 北京协和医学院 北京协和医院风湿免疫科100730 北京,中国医学科学院 北京协和医学院 北京协和医院风湿免疫科100730 北京,中国医学科学院 北京协和医学院 北京协和医院风湿免疫科100730 北京,中国医学科学院 北京协和医学院 北京协和医院风湿免疫科100730 北京,中国医学科学院 北京协和医学院 北京协和医院消化内科100730 北京,中国医学科学院 北京协和医学院 北京协和医院消化内科100730 北京,中国医学科学院 北京协和医学院 北京协和医院风湿免疫科100730 北京,中国医学科学院 北京协和医学院 北京协和医院风湿免疫科100730 北京,中国医学科学院 北京协和医学院 北京协和医院风湿免疫科
肠白塞病巴瑞替尼
intestinal Behçet's diseasebaricitinib
《中华临床免疫和变态反应杂志》 2026 (4)
276-282,7
评论